The Mail on Sunday

MIDAS VERDICT:

-

At £9.30, Ergomed shares have done well this year, benefiting from increased investor interest in almost all healthcare stocks. However, the company is profitable, its balance sheet is robust and the shares should continue to rise as Reljanovic and Barfield roll out their strategy. Buy.

Newspapers in English

Newspapers from United Kingdom